Table 1

Demographics and clinical characteristics of patients in Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China (N=1440)

Women (n=541)Men (n=899)P value
Age, years, mean (SD)66.2±11.261.0±11.3<0.001
Clinical features
 Systolic BP, mm Hg (IQR)150(135-162)148(132-162)0.24
 Diastolic BP, mm Hg (IQR)85 (78–91)89 (80–97)<0.001
 Glucose, mmol/L (IQR)6.8 (5.8–8.8)6.8 (5.8–8.4)0.06
 Current smoking, n (%)25 (4.6)490 (54.4)<0.001
Medical history
 Previous ischaemic stroke, n (%)96 (17.7)151 (16.8)0.64
 Previous TIA, n (%)42 (9.3)84 (9.3)0.30
 Hypertension, n (%)337 (62.3)507 (56.4)0.03
 Hyperlipidaemia, n (%)35 (6.5)59 (6.6)0.94
 Diabetes mellitus, n (%)116 (21.4)140 (15.6)0.005
 Atrial fibrillation, n (%)137 (25.3)101 (11.2)<0.001
Baseline medication
Antiplatelets use before stroke, n (%)79 (14.6)112 (12.5)0.25
Anticoagulants use before stroke, n (%)9 (1.7)15 (1.7)0.99
Antihypertensive agents before stroke, n (%)236 (43.6)296 (32.9)<0.001
Prestroke mRS 0–2, n (%)528 (97.8)884 (98.7)0.21
Median NIHSS on admission, mean (SD)12.3±6.811.6±6.70.04
Median stroke-to-visit time, min (IQR)1.2 (0.7–2.0)1.3 (0.8–2.2)0.04
Median stroke-to-imaging time, min (IQR)1.9 (1.3–2.9)1.8 (1.3–2.6)0.03
Median stroke-to-needle time, min0.04
 0–3 hours, n (%)305 (56.5)449 (50.2)
 3–4.5 hours, n (%)135 (25.0)239 (26.7)
 >4.5 hours, n (%)100 (18.5)207 (23.1)
TOAST type<0.001
 LAA, n (%)272 (50.5)549 (61.7)
 SAO, n (%)44 (8.2)83 (9.3)
 CE, n (%)143 (26.6)116 (13.0)
 Other, n (%)79 (14.7)142 (16.0)
Total length of stay (days)15 (11–21)14 (11–21)0.10
  • BP, blood pressure; CE, cardioembolism; LAA, large-artery atherosclerosis; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; SAO, small-artery occlusion; TIA, transient ischaemic attack; TOAST, Trial of Org 10172 in Acute Stroke Treatment.